Company intelligence / Profile preview

Cepheid

Sunnyvale, California, United Statescepheid.com ↗

Ownership: Public · DHR
Employees: ~2500
Development stage: Commercial

Overview

Cepheid’s GeneXpert platform enables rapid molecular diagnostic testing for a broad range of infectious diseases and some oncology applications. The company’s Xpert MTB/RIF test for tuberculosis was a major innovation endorsed by the WHO. Its platforms are widely used globally in clinical labs and point-of-care settings. Clinical results have demonstrated high sensitivity/specificity for many assays.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Device (molecular diagnostics platform)PCR-based diagnostic tests
Industry: Molecular Diagnostics

Partnerships

Northrop Grumman – biothreat detection systems for USPSFIND – TB/HIV diagnostics development partnershipBill & Melinda Gates Foundation – funding support for global health initiatives

Beyond the preview

Go deeper on Cepheid.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cepheid.

Explore the full profile